Next-generation sequencing based testing for breast cancer

Shridar Ganesan; Kim M. Hirshfield

doi:10.1007/978-3-319-41761-5_20

Next-generation sequencing based testing for breast cancer

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The breast cancer can be sporadic or familial. Studies in the early 1990s lead to the recognition of the role of BRCA1 and BRCA2 genes in hereditary breast cancer. Next generation sequencing (NGS) technologies have permitted expansion of the number of genes that can be simultaneously analyzed for assessment of breast cancer risk. NGS has opened a large window into the complex biology of carcinogenesis and management of breast cancer. Mutation panels are now being commonly used in the making therapeutic decisions. In this chapter, we review the data on the gene panels being used for risk assessment and clinical management of patients and discuss the pros and cons of the approaches.

Original language	English (US)
Title of host publication	Molecular Pathology of Breast Cancer
Publisher	Springer International Publishing
Pages	299-328
Number of pages	30
ISBN (Electronic)	9783319417615
ISBN (Print)	9783319417592
DOIs	https://doi.org/10.1007/978-3-319-41761-5_20
State	Published - Jan 1 2016

All Science Journal Classification (ASJC) codes

Medicine(all)

Keywords

Mutation panels
NGS
Risk assessment
Therapy

Access to Document

10.1007/978-3-319-41761-5_20

Fingerprint Dive into the research topics of 'Next-generation sequencing based testing for breast cancer'. Together they form a unique fingerprint.

Cite this

@inbook{2f8c576dc3f446f3b91b7b19a5d94b95,

title = "Next-generation sequencing based testing for breast cancer",

abstract = "The breast cancer can be sporadic or familial. Studies in the early 1990s lead to the recognition of the role of BRCA1 and BRCA2 genes in hereditary breast cancer. Next generation sequencing (NGS) technologies have permitted expansion of the number of genes that can be simultaneously analyzed for assessment of breast cancer risk. NGS has opened a large window into the complex biology of carcinogenesis and management of breast cancer. Mutation panels are now being commonly used in the making therapeutic decisions. In this chapter, we review the data on the gene panels being used for risk assessment and clinical management of patients and discuss the pros and cons of the approaches.",

keywords = "Mutation panels, NGS, Risk assessment, Therapy",

author = "Shridar Ganesan and Hirshfield, {Kim M.}",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-41761-5_20",

language = "English (US)",

isbn = "9783319417592",

pages = "299--328",

booktitle = "Molecular Pathology of Breast Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Next-generation sequencing based testing for breast cancer

AU - Ganesan, Shridar

AU - Hirshfield, Kim M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The breast cancer can be sporadic or familial. Studies in the early 1990s lead to the recognition of the role of BRCA1 and BRCA2 genes in hereditary breast cancer. Next generation sequencing (NGS) technologies have permitted expansion of the number of genes that can be simultaneously analyzed for assessment of breast cancer risk. NGS has opened a large window into the complex biology of carcinogenesis and management of breast cancer. Mutation panels are now being commonly used in the making therapeutic decisions. In this chapter, we review the data on the gene panels being used for risk assessment and clinical management of patients and discuss the pros and cons of the approaches.

AB - The breast cancer can be sporadic or familial. Studies in the early 1990s lead to the recognition of the role of BRCA1 and BRCA2 genes in hereditary breast cancer. Next generation sequencing (NGS) technologies have permitted expansion of the number of genes that can be simultaneously analyzed for assessment of breast cancer risk. NGS has opened a large window into the complex biology of carcinogenesis and management of breast cancer. Mutation panels are now being commonly used in the making therapeutic decisions. In this chapter, we review the data on the gene panels being used for risk assessment and clinical management of patients and discuss the pros and cons of the approaches.

KW - Mutation panels

KW - NGS

KW - Risk assessment

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85009659145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009659145&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-41761-5_20

DO - 10.1007/978-3-319-41761-5_20

M3 - Chapter

AN - SCOPUS:85009659145

SN - 9783319417592

SP - 299

EP - 328

BT - Molecular Pathology of Breast Cancer

PB - Springer International Publishing

ER -